Steris Plc (NYSE:STE) insider Michael J. Tokich sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $92.00, for a total transaction of $1,012,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Steris Plc (NYSE:STE) traded down 0.04% on Tuesday, hitting $91.23. 275,777 shares of the company’s stock traded hands. Steris Plc has a 12 month low of $63.80 and a 12 month high of $92.20. The stock has a 50 day moving average price of $88.58 and a 200-day moving average price of $81.84. The stock has a market cap of $7.78 billion, a P/E ratio of 65.26 and a beta of 1.29.

Steris Plc (NYSE:STE) last issued its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported $0.85 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.80 by $0.05. The business had revenue of $608.00 million for the quarter, compared to analysts’ expectations of $597.66 million. Steris Plc had a return on equity of 11.39% and a net margin of 4.63%. The company’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.79 EPS. Equities analysts predict that Steris Plc will post $4.06 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Tuesday, August 29th were issued a dividend of $0.31 per share. This represents a $1.24 annualized dividend and a dividend yield of 1.36%. This is a boost from Steris Plc’s previous quarterly dividend of $0.28. The ex-dividend date was Friday, August 25th. Steris Plc’s dividend payout ratio is 88.57%.

COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/24/steris-plc-ste-insider-michael-j-tokich-sells-11000-shares.html.

A number of large investors have recently added to or reduced their stakes in STE. First Trust Advisors LP raised its holdings in Steris Plc by 14.0% during the 1st quarter. First Trust Advisors LP now owns 8,593 shares of the medical equipment provider’s stock valued at $597,000 after buying an additional 1,055 shares during the period. Parametric Portfolio Associates LLC raised its holdings in Steris Plc by 18.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 23,513 shares of the medical equipment provider’s stock valued at $1,633,000 after buying an additional 3,683 shares during the period. JPMorgan Chase & Co. raised its holdings in Steris Plc by 2.3% during the 1st quarter. JPMorgan Chase & Co. now owns 67,052 shares of the medical equipment provider’s stock valued at $4,657,000 after buying an additional 1,490 shares during the period. Neuberger Berman Group LLC raised its holdings in Steris Plc by 71.3% during the 1st quarter. Neuberger Berman Group LLC now owns 7,635 shares of the medical equipment provider’s stock valued at $530,000 after buying an additional 3,179 shares during the period. Finally, OppenheimerFunds Inc. raised its holdings in Steris Plc by 22.6% during the 1st quarter. OppenheimerFunds Inc. now owns 9,332 shares of the medical equipment provider’s stock valued at $648,000 after buying an additional 1,722 shares during the period. Institutional investors own 94.13% of the company’s stock.

Several research analysts have commented on the stock. Zacks Investment Research raised shares of Steris Plc from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a research note on Monday, October 9th. KeyCorp reissued a “buy” rating and set a $91.00 price target on shares of Steris Plc in a research note on Tuesday, October 17th. Raymond James Financial, Inc. lifted their price target on shares of Steris Plc from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Finally, BidaskClub downgraded shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $90.75.

Steris Plc Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Insider Buying and Selling by Quarter for Steris Plc (NYSE:STE)

Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.